Centre for Applied Genomics

Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7

Retrieved on: 
Wednesday, November 1, 2023
Massachusetts General Hospital, Research, Centre for Applied Genomics, Harvard Medical School, Heart failure, MD, Cardiology, Webcast, Therapy, Diabetic cardiomyopathy, Pharmaceutical industry, Broadcasting, Medical device

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will host a Diabetic Cardiomyopathy (DbCM) expert forum with key opinion leaders on Tuesday, November 7, 2023 at 8:00 a.m. ET.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will host a Diabetic Cardiomyopathy (DbCM) expert forum with key opinion leaders on Tuesday, November 7, 2023 at 8:00 a.m.
  • ET.
  • Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com.
  • A replay of the webcast will be archived on the Company’s website following the forum.

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Retrieved on: 
Tuesday, August 22, 2023
Research, Other Health, Pharmaceutical, Oncology, Medical Devices, Hospitals, Genetics, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, Other Science, Pressure, DNA, Fisher Scientific, Centre for Applied Genomics, Thermo Fisher Scientific, Chas, Amniotic fluid, Data analysis, Genome, AIR, Blood, GCS, Saliva, Management, Medical imaging

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.
  • “Thermo Fisher Scientific is committed to innovation to meet the needs of our customers,” said Kevin Lowitz, vice president and general manager, microarray genetic solutions, Thermo Fisher Scientific.
  • As part of its commitment to enabling customers to advance cytogenetic research, Thermo Fisher has continued to update its instrumentation and services.
  • Thermo Fisher has also upgraded its high-performance microarray instrument for array processing, Applied Biosystems™ GeneChip™ System (GCS) 3000 , with the autoloader pre-assembled inside the scanner for more efficient installation and a modernized look.

PAULA'S CHOICE LAUNCHES NEW BEAUTYPEDIA SKIN CARE INGREDIENT CHECKER, SETTING A NEW INDUSTRY STANDARD IN INGREDIENT TRANSPARENCY IN SKINCARE

Retrieved on: 
Thursday, April 27, 2023
Genetics, Skin care, Choice, Anatomy, Environmental science, Centre for Applied Genomics, Physiology, Research, Science, Dermatology, Science Advisory Board, Skin, Safety, Cosmetics

NEW YORK, April 27, 2023 /PRNewswire/ -- Research-based skin care brand Paula's Choice announces the launch of its new Beautypedia Skin Care Ingredient Checker, an innovative decoding tool that allows consumers to instantly analyze the ingredients in any skin care product in seconds, cut through trend-based hype and learn how the ingredients rate based on cited scientific research.

Key Points: 
  • In an industry first, Paula's Choice launches breakthrough online tool to put knowledge in the hands of the consumer to be the best advocate for their own skin.
  • The Beautypedia Skin Care Ingredient Checker delivers the most comprehensive and accurate formula analysis available, relying on scientific facts instead of fearmongering.
  • If there are any BAD/WORST ingredients, you'll be given the option to explore alternative products better suited for your skin.
  • Paula's Choice new Beautypedia Skin Care Ingredient Checker can be found on the brands website: https://www.paulaschoice.com/beautypedia-ingredient-checker .

MGI Announces Commercial Launch of HotMPS High-Throughput Sequencing Kit* and Instrument** in Germany

Retrieved on: 
Tuesday, September 6, 2022
Software, Enzyme, Medical genetics, Technology, BGI Group, Research, Agriculture, YouTube, Wehrheim, Precision medicine, Nucleotide, University, LinkedIn, MUST, Centre for Applied Genomics, Laboratory, Patent, CPAS, Annual general meeting, MEDICA, Conference, Twitter, Risk, Institute, MGI, International Conference on Availability, Reliability and Security, General manager, Fine chemical, Hydraulic machinery, Genomics, European

WEHRHEIM, Germany, Sept. 6,2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, has announced the commercial availability of its innovative HotMPS reagents* and sequencing instrument** in Germany as of 9 August 2022.

Key Points: 
  • WEHRHEIM, Germany, Sept. 6,2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, has announced the commercial availability of its innovative HotMPS reagents* and sequencing instrument** in Germany as of 9 August 2022.
  • Meanwhile, the DNBSEQ-G400** sequencing platform (for HotMPS exclusively) will be presented at MEDICA 2022 on 14-17 November in Dsseldorf.
  • MGI will also attend the 32nd GfH Annual Meeting on 15-17 March 2023 in Kassel as a sponsor.
  • "As our trusted partner, we are excited about MGI's HotMPS chemistry* arriving in Germany and the new research advances it will enable."

SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding™ Platform

Retrieved on: 
Wednesday, July 20, 2022
Novartis, Genetic engineering, Centre for Applied Genomics, Gene, Genetics, RNA transfection, Sanofi–Translate Bio COVID-19 vaccine, Technology, Pfizer, LinkedIn, Harvard Medical School, Regulation, Drug, Research, Biotechnology, MBA, Infection, SVP, AstraZeneca, Growth, Automation, GLOBE, Physician, ATMP, Industry, Medicine, Twitter, Patent, COVID-19, Novartis Institute for Tropical Diseases, Publication, FDA, Cancer, Therapy, Gene editing, Coding, Biomedical Research, Forward-looking statement, Natera, Associate, Biomarker discovery, Biomarker, Hospital, Leadership, Takeda Pharmaceutical Company, Senior, Genetics Institute, Patient, EDIT, Pharmaceutical industry, Management, Vaccine, Brigham, Takeda, Genomics, Genzyme, Policy, Moderna, Operation

We look forward to benefitting from their leadership as they help to maximize the potential impact of Gene Coding not only on the genetic medicines industry, but on patients around the world.

Key Points: 
  • We look forward to benefitting from their leadership as they help to maximize the potential impact of Gene Coding not only on the genetic medicines industry, but on patients around the world.
  • She also served as the acting Chief Medical Officer at clinical-stage gene therapy company Solid Biosciences.
  • Joe Senn, Ph.D. has experience with nearly all therapeutic modalities, including small molecules, biologics, antisense, gene editing and mRNA therapeutics.
  • SalioGen Therapeutics has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration TechnologyTM (EDITTM) platform.

PacBio Supports SickKids to Investigate Use of HiFi Sequencing in Undiagnosed Genetic Conditions

Retrieved on: 
Monday, February 28, 2022
Molecule, GLOBE, Securities Exchange Act of 1934, TCAG, Autism, Single-molecule real-time sequencing, Security (finance), Abraxis BioScience, NASDAQ, Centre for Applied Genomics, Diagnosis, Hospital, Whole genome sequencing, Genomics, Research, Genome, Company, Pacific Biosciences, Associate, Genetic testing, Birth, U.S. Securities and Exchange Commission, Hospital for Sick Children, Lists of diseases, Biomedical Research, Intellectual disability, Structural variation in the human genome, High fidelity, Hospital for Sick Children (Toronto), Clinical Laboratory, Technology, Genetic variation, Microbiology, Private Securities Litigation Reform Act, The Centre, Vaccine, Antibiotics

Samples that will be examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology, but still lack the identification of a disease-causing variant.

Key Points: 
  • Samples that will be examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology, but still lack the identification of a disease-causing variant.
  • SickKids will use HiFi WGS to analyze samples from research participants who are highly suspected to have a genetic condition but have not yet received a diagnosis despite previous genetic testing, including srWGS.
  • The team will explore whether HiFi WGS can detect potential genetic causes for a range of conditions, such as autism spectrum disorder and congenital diseases.
  • PacBios technology has been used to help genetic disease researchers explain mysteries where other technologies could not, said Edd Lee, Director of Human Genomics at PacBio.

PerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management

Retrieved on: 
Monday, November 22, 2021
Technology, Biotechnology, Engineering, Chemicals, Plastics, Health, Other Energy, Manufacturing, Other Health, Energy, Pharmaceutical, Environment, Medical Devices, General Health, Hardware, GX, G3, PerkinElmer, Company, Genomics, Centre for Applied Genomics, Solution, Longevity, SMS, Science, Quality control, Food, Quality of life, Video game console

With the PKeye Workflow Monitor, researchers can confidently walk away from their laboratory instruments without concern of disruptions to productivity or throughput, said James Atwood, general manager of Applied Genomics, PerkinElmer.

Key Points: 
  • With the PKeye Workflow Monitor, researchers can confidently walk away from their laboratory instruments without concern of disruptions to productivity or throughput, said James Atwood, general manager of Applied Genomics, PerkinElmer.
  • Through instant notifications and remote web-access, this platform provides users with confidence that their samples are moving efficiently through extraction, quality control and liquid handling processes.
  • The PKeye Workflow Monitor is currently able to facilitate visual monitoring of the PerkinElmer JANUS G3 , Sciclone G3 and Zephyr G3 workstations.
  • We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.

Leading OB/GYNs and Scientists join Evvy's Advisory Board to Guide Novel Research on Critical Female Biomarkers

Retrieved on: 
Tuesday, October 19, 2021
University of Pittsburgh, Biomarker, Genetics, Epidemiology, Vaginitis, TIA, Woman, Infertility, Risk, Cleveland Clinic, Reproductive Sciences, Prenatal development, Harvard University, General Catalyst, Michigan Medicine, Pelvic inflammatory disease, Multimedia, Department, Los Alamos National Laboratory, Research, Reproduction, Stanford University, Assistant professor, CEO, Associate professor, Female, The Advisory Board Company, UCSF, Health, Faculty, Hinds, University, Reproductive health, Centre for Applied Genomics, Vulvar vestibulitis, Birth control, Management

Simultaneously, Evvy is discovering how new biomarkers can be leveraged to predict risk, diagnose, and treat a variety of critical health conditions in the female body.

Key Points: 
  • Simultaneously, Evvy is discovering how new biomarkers can be leveraged to predict risk, diagnose, and treat a variety of critical health conditions in the female body.
  • The Evvy Advisory Board confirmed its first seven members, which include top OB/GYNs, researchers, and at-home testing experts:
    Dr. Craig Cohen, OB/GYN and Professor of OB/GYN & Reproductive Sciences at UCSF.
  • Dr. Ava Manieri, Head of Research at Tia, genetics PhD from Harvard with deep expertise in female reproductive health.
  • Simultaneously, Evvy is discovering how new biomarkers can be leveraged to predict risk, diagnose, and treat a variety of critical health conditions in the female body.

Pure Sunfarms signs groundbreaking cannabis research partnership with Langara College

Retrieved on: 
Tuesday, September 28, 2021
Goal, BC Liquor Distribution Branch, Partnership, AGLC, Centre for Applied Genomics, Adult education, Delta 3 greenhouse, Student, Ontario Cannabis Retail Corporation, Natural Sciences and Engineering Research Council, OCS, Genetic drift, Chemistry, Saskatchewan, Pure, Biology, GLOBE, CFI, CEO, University, Musqueam Indian Band, BCLDB, NSERC, Breeding, Technology, Natural science, Cannabis, Saskatchewan Liquor and Gaming Authority, Research, Manitoba Liquor Control Commission, Innovation, SLGA, College, Industry, Education, Langara College, Management, Medicine

The partnership allows the ASCCI research team to harness Pure Sunfarms research and development expertise to achieve the project goals.

Key Points: 
  • The partnership allows the ASCCI research team to harness Pure Sunfarms research and development expertise to achieve the project goals.
  • With Langara College, we hope to produce research findings that will allow us to optimize the quality of our products and advance Canadas cannabis industry, saidMandeshDosanjh, President and CEO of Pure Sunfarms.
  • Pure Sunfarms brings a wealth of industry experience to theASCCI research project, said Kelly Sveinson, Director, Langara College Applied Research Centre.
  • Researchers and students at Langara will benefit from close collaboration with Pure Sunfarms research and development team through the partnership.

New York Genome Center Creates International Scientific Advisory Board

Retrieved on: 
Wednesday, December 9, 2020
Branches of biology, DNA sequencing, New York Genome Center, Genetics, Biology, Genomics, Tom Maniatis, Centre for Applied Genomics, Genome Research

NEW YORK, Dec. 9, 2020 /PRNewswire/ --The New York Genome Center (NYGC) announced today that it has created a Scientific Advisory Board (SAB) to provide counsel and support for the organization's scientific mission.

Key Points: 
  • NEW YORK, Dec. 9, 2020 /PRNewswire/ --The New York Genome Center (NYGC) announced today that it has created a Scientific Advisory Board (SAB) to provide counsel and support for the organization's scientific mission.
  • Composed of leading international genomic scientists, the 10-member board offers guidance and valuable input on research strategy from diverse perspectives to the NYGC's Evnin Family Scientific Director and CEO, Tom Maniatis, PhD.
  • The wide-ranging expertise of the advisory board includes: quantitative human genetics, neurogenetics, functional genomics, genomic technology development, computational biology, machine learning, population genomics, and cancer genomics.
  • The New York Genome Center (NYGC) is an independent, nonprofit academic research institution that serves as a multi-institutional hub for genomic research.